Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

Dan P. Zandberg, Alain P. Algazi, Antonio Jimeno, James S. Good, Jérôme Fayette, Nathaniel Bouganim, Neal E. Ready, Paul M. Clement, Caroline Even, Raymond W. Jang, Stuart Wong, Ulrich Keilholz, Jill Gilbert, Moon Fenton, Irene Braña, Stephanie Henry, Eva Remenar, Zsuzsanna Papai, Lillian L. Siu, Anthony JarkowskiJon M. Armstrong, Kobby Asubonteng, Jean Fan, Giovanni Melillo, Ricard Mesía

Research output: Contribution to journalArticle

35 Citations (Scopus)

Fingerprint Dive into the research topics of 'Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences